Valbiotis Announces Its Roadmap for 2023: a Pivotal Year in

A decisive year in clinical terms with results expected in the first half of 2023 from the international Phase II/III REVERSE-IT study on TOTUM•63, a plant-based active substance that has already

Related Keywords

Quebec , Canada , France , Riom , Auvergne , French , , European Regional Development Fund , Health Science , Research Development , Young Innovative Company , Valbioti Business Development Department , Public Affairs , European Union , Innovative Company , Valbioti Business Development , Valbiotis Board , Quebec City , Valbiotis Universal Registration Document , French Financial Markets Regulator , Valbiotis , Nnounces , Roadmap , 023 , Pivotal , Ear , Execution , Linical , Industrial , Commercial , Strategy ,